User profiles for "author:J Seymour"
John F SeymourProfessor of Medicine, Director Dept of Haematology Peter MacCallum Cancer Centre & … Verified email at petermac.org Cited by 65738 |
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
M Hallek, BD Cheson, D Catovsky… - Blood, The Journal …, 2018 - ashpublications.org
The previous edition of the consensus guidelines of the International Workshop on Chronic
Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by …
Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by …
Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care
…, DJA Janssen, L Orsi, S Payne, J Seymour… - The Lancet …, 2017 - thelancet.com
Advance care planning (ACP) is increasingly implemented in oncology and beyond, but a
definition of ACP and recommendations concerning its use are lacking. We used a formal …
definition of ACP and recommendations concerning its use are lacking. We used a formal …
Pulmonary alveolar proteinosis: progress in the first 44 years
JF Seymour, JJ Presneill - … journal of respiratory and critical care …, 2002 - atsjournals.org
Pulmonary alveolar proteinosis is a rare clinical syndrome that was first described in 1958.
Subsequently, over 240 case reports and small series have described at least 410 cases in …
Subsequently, over 240 case reports and small series have described at least 410 cases in …
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
AJ Souers, JD Leverson, ER Boghaert, SL Ackler… - Nature medicine, 2013 - nature.com
Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic
process. This family comprises proapoptotic and prosurvival proteins, and shifting the …
process. This family comprises proapoptotic and prosurvival proteins, and shifting the …
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase …
P Fenaux, GJ Mufti, E Hellstrom-Lindberg… - The lancet …, 2009 - thelancet.com
Background Drug treatments for patients with high-risk myelodysplastic syndromes provide
no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall …
no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Background On the basis of promising results that were reported in several phase 2 trials,
we investigated whether the addition of the monoclonal antibody rituximab to first-line …
we investigated whether the addition of the monoclonal antibody rituximab to first-line …
[HTML][HTML] Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia
AW Roberts, MS Davids, JM Pagel… - … England Journal of …, 2016 - Mass Medical Soc
Background New treatments have improved outcomes for patients with relapsed chronic
lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a …
lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a …
Acute skeletal muscle wasting in critical illness
…, R Phadke, T Dew, PS Sidhu, C Velloso, J Seymour… - Jama, 2013 - jamanetwork.com
Importance Survivors of critical illness demonstrate skeletal muscle wasting with associated
functional impairment. Objective To perform a comprehensive prospective characterization …
functional impairment. Objective To perform a comprehensive prospective characterization …
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts
H Dombret, JF Seymour, A Butrym… - Blood, The Journal …, 2015 - ashpublications.org
This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and
safety vs conventional care regimens (CCRs) in 488 patients age≥ 65 years with newly …
safety vs conventional care regimens (CCRs) in 488 patients age≥ 65 years with newly …